Minerva Neurosciences (NERV) Free Cash Flow (2013 - 2026)
Minerva Neurosciences (NERV) posted Free Cash Flow of -$5.4 million for Q1 2026, down 20.0% on a QoQ basis from -$4.5 million in Q4 2025, and down 32.61% year-over-year from -$8.0 million in Q1 2025.
Minerva Neurosciences (NERV) Free Cash Flow (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Free Cash Flow history runs 14 years deep, the most recent figure standing at -$5.4 million for Q1 2026.
- Quarterly Free Cash Flow fell 32.61% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.8 million (up 15.4% YoY) and the FY2025 annual result came in at -$13.5 million, up 30.95% from the prior year.
- Free Cash Flow was -$5.4 million for Q1 2026 at Minerva Neurosciences, down from -$4.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$115407.0 in Q1 2023 and bottomed at -$9.5 million in Q3 2022.
- A 5-year average of -$4.6 million and a median of -$4.5 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 98.01% — and 2024, when it sank 5180.68%.
- Minerva Neurosciences' Free Cash Flow stood at -$4.1 million in 2022, then plunged by 45.77% to -$6.0 million in 2023, then rose by 13.76% to -$5.2 million in 2024, then grew by 12.91% to -$4.5 million in 2025, then declined by 20.0% to -$5.4 million in 2026.
- Business Quant data shows NERV's Free Cash Flow at -$5.4 million in Q1 2026, -$4.5 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.40 Mn |
| Mar 31, 2026 | -5.40 Mn |
| Dec 31, 2025 | -4.50 Mn |
| Dec 31, 2025 | -4.50 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Dec 31, 2023 | -5.99 Mn |
| Dec 31, 2023 | -5.99 Mn |